{"id":1386,"date":"2026-02-14T12:36:22","date_gmt":"2026-02-14T12:36:22","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/14\/what-is-vidofludimus\/"},"modified":"2026-02-14T12:36:22","modified_gmt":"2026-02-14T12:36:22","slug":"what-is-vidofludimus","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/02\/14\/what-is-vidofludimus\/","title":{"rendered":"What is Vidofludimus?"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F02%2Fwhat-is-vidofludimus%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>Although it sounds like a character out of Gladiator III&#8230;.Vidofludimus (calcium) is not a Russel Crowe look alike&#8230;but it is a teriflunomide look alike. It is not a generic of teriflunomide but works in the same way.<\/p>\n<p>Teriflunomide is the active breakdown product of leflunomide which is used in rheumatoid arthritus. So would leflunomide work in MS, yep it would because you give leflunomide and within a few minutes\/hours the body turns it in teriflunomide. The Boffins thought let&#8217;s cut out the middleman\/woman and simply give the active compound. This can be patented and allows the companies to grease their palms. As teriflunomides patent runs out you could make a generic or do something to give a patent so you can make more money if you can make improvements over the former compound. We have seen this over and over again&#8230;You can adapt the original drug either manipulate it to give a different does or route Copaxone daily to become three times a week and then as a depot once a month (Remember it is a random mix of amino acids and each batch is different)&#8230;..Avonex beta interferon-1a once a week to become plegridy (pegylated avonex beta interferfon-1a with anti-freeze i.e polyethylene glycol) once every two weeks, natalizumab gives way to subcutaneous natalizumab, ocrelizumab becomes subcutaneous ocrelizumab (Ocrevus zunovo), alemtuzumab become&#8230;nothing because it has collected too much baggage and it is hardly used so it was probably not considered worth it to develop a me too. An alternative is to develop another agent that works in the same way as the originator fingolimod targets sphingosine-1-phopshate as a mechanism of action in MS so does siponimod, ozanimod and ponsesimod, dimethyl fumarate works because it is degraded into monomethyl fumarate so alternative is make a drug that is monomethyl fumarate or another one diroximel fumarate that also breaks down to monmethyl fumarate and guess what pharma has been inventive and made a molecule that blocks <a href=\"https:\/\/en.wikipedia.org\/wiki\/Dihydroorotate_dehydrogenase\">dihydroorotate dehydrogenase<\/a> just like teriflunomide and may be more effective on the target and so it will have a similar side effect potential and will be anti-proliferative. It make not target some of the off-target effects of teriflunomide but it also activates nuclear receptor-related 1 (<a href=\"https:\/\/en.wikipedia.org\/wiki\/Nuclear_receptor_4A2\">Nurr1<\/a>), a neuroprotective\u00a0<a href=\"https:\/\/en.wikipedia.org\/wiki\/Transcription_factor\">transcription factor<\/a>\u00a0and emerging target for\u00a0<a href=\"https:\/\/en.wikipedia.org\/wiki\/Neurodegenerative_disease\">neurodegenerative diseases<\/a>. Activation of Nurr1 is associated with neuroprotective effects.<\/p>\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"92\" src=\"https:\/\/multiple-sclerosis-research.org\/wp-content\/uploads\/2026\/02\/image-1.png\" alt=\"\" class=\"wp-image-55170\" style=\"width:410px;height:auto\" \/><\/figure>\n<\/div>\n<p>Data from a early trial in progressive MS is presenteted at ACTRIMS 2026 but it has <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11087024\/\">been trialed in relapsing MS<\/a> the (CALLIPER trial). A weird name. Is it after a device that gives precision to measuring things but it is also another name for a brace\/orthoses for spastic legs. Phase III trials have been done ENSURE I &amp; II NCT05201638\/NCT05134441. Let&#8217;s see where they go will they be better than whats out there. It is suggested that it is an EBV inhibitor <a href=\"https:\/\/imux.com\/wp-content\/uploads\/2026\/02\/Poster-ACTRIMS-2026-Effect-of-Vidofludimus-Calcium-on-Anti-EBV-T-cell-Receptor-Repertoire-in-PMS.pdf\">presented at ACTRIMS2026<\/a>. This has been suggested previously for teriflunomide. I would say it has to be a weak inhibitor because we know that you can do better as teriflunomide is not a high efficacy treatment.<\/p>\n<p>Me COI: Non-relevant<\/p>\n<p>Disclaimer: My views<\/p>\n<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/02\/what-is-vidofludimus\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-is-vidofludimus\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet Although it sounds like a character out of Gladiator III&#8230;.Vidofludimus (calcium) is not a Russel Crowe look alike&#8230;but it is a teriflunomide look alike. It is not a generic of teriflunomide but works in the same way. Teriflunomide is the active breakdown product of leflunomide which is used in rheumatoid arthritus. So would leflunomide&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1387,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1386"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1387"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}